Stimunity

Sitmunity is preclinical-stage start-up company which develops best-in-class drugs on the STING pathway to activate the innate immune system. Its drugs stimulate patients' immune system to fight back infectious pathogens or cancer.

Year of creation: 2016

Line of business: Biotechnology

Institut Curie: Behind the technology and R&D partner

TECHNOLOGY

Stimunity leverages an immuno-modulator platform based on Virus-Like Particles.

STING activates the dendritic cells and induces a cytotoxic T lymphocytes response against infectious pathogens or cancer. However, this pathway is challenging to activate. Small molecules do not penetrate through the cell membranes which requires high dose of drug and limits the drug to local injections. There is a way to do better. The company's Virus-Like Particle vectorizes the best known STING activator, cGAMP. With this system, Stimunity can achieve very high activation of the STING pathway, targets a specific cell type for systemic administration, and induces an immune response against infectious pathogens or tumors.

APPLICATIONS

Immuno-oncology and infectious pathogens.

More about Stimunity:

• Stimunity signs an exclusive license agreement with Institut Curie and Inserm
• Stimunity, a major advance for new immunotherapy